Tokyo, Japan and Cambridge and London, UK, 15 July 2026. Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.
The Company will host a live webinar presentation with:
- Chris Cargill, President, CEO
- Hironoshin Nomura, CFO
- Toshi Maeda, COO
- Patrik Foerch, CSO and President of Nxera Pharma UK
at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026.
The webinar is open to all existing and potential investors as well as sell-side and buy-side analysts, and will consist of a presentation followed by a Q&A session.
Distribution
This announcement is distributed via GlobeNewswire and released simultaneously in Tokyo, Japan and Cambridge and London, UK, in accordance with the disclosure requirements of the Tokyo Stock Exchange (TSE: 4565).
About Nxera Pharma
Nxera Pharma is a technology-powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region.
In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies, powered by its unique NxWave™ GPCR structure-based drug discovery platform.
Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea), and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life
Enquiries:
Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations +81 (0)3 5210 3399 | +44 (0)1223 949390 | [email protected]
MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | [email protected]
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products.
Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors.
As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.